Mood Disorders News

A mobile cognitive training app for depression may be effective for moderate and late-life depression, according to recent findings.

Results from a systematic review and meta-analysis suggested bilateral and priming low-frequency repetitive transcranial magnetic stimulation were most effective for major depressive disorder; however, data were limited.

NeuroRx recently announced the FDA accepted an Investigational New Drug application for NRX-101, an oral fixed-dose combination of D-Cycloserine and lurasidone, for acute suicidal ideation and behavior in bipolar depression.

The FDA has granted orphan drug designation to ganaxolone for the treatment of Fragile X syndrome, the most common genetic cause of autism, according to a press release from Marinus Pharmaceuticals.

Among individuals with schizophrenia spectrum disorders, major depressive disorder with psychosis and bipolar disorder with psychosis, impaired social functioning was most common in schizophrenia.

A systematic review supported the elevation of activation to a criterion A symptom for bipolar disorder in DSM-5.

In 2014, an estimated 43.6 million adults aged 18 years or older, or 18.1% of all U.S. adults, had any mental illness in the past year, excluding substance use disorders, according to the NIMH.

Lower IQ was associated with past-year fear and distress disorders and was not associated with PTSD, anxiety or eating disorders, according to recent findings.

Lifetime substance use was associated with postpartum mood disorders, according to recent findings.

The NIH’s National Institute of Nursing Research recently awarded a $2 million grant to nurse researchers at Case Western Reserve University to study the well-being of caregivers of relatives with bipolar disorder.